Cramer says this aerospace stock is significantly undervalued, sees 35% upside

Stocks rose Tuesday as investors looked to cap a strong first half despite ongoing Middle East uncertainty, with WTI crude holding just above $70/bbl after the U.S. and Iran agreed to halt attacks and reopen Strait of Hormuz passage. In the AI trade, Jim favored semiconductor suppliers like Micron over hyperscalers financing capex, citing “clear, multi-year demand visibility.” Club holdings also stayed strong—Cardinal Health continued rebounding after an “unjustified” sell-off and Jim suggested it “may not be done going higher,” while Honeywell Aerospace rose ~2% on its separation, with Jim arguing the market is materially undervaluing the aerospace franchise (implied ~35% upside).

Analysis

The cleanest read-through is that the market is rewarding visibility and punishing duration risk. In AI, the next leg of outperformance likely accrues to suppliers with shorter payback cycles and more direct pricing power than the hyperscalers funding the capex binge; that makes memory and other component names more levered to an actual earnings inflection than the platform names that are still being asked to spend ahead of revenue. The risk is that this is a second-order rotation, not a new-cycle signal: if cloud capex merely normalizes or shifts toward networking/ASICs, names like MU can lag even while AI demand stays intact.

Healthcare looks more like a mean-reversion trade than a new fundamental regime. CAH has the best setup because the rerating is less about heroic growth and more about the market undoing a prior multiple discount, while LLY remains a structural compounder but is already crowded and vulnerable to any disappointment on pricing, access, or obesity prescription growth. If rates fall and cyclicals reassert leadership, this rotation can unwind quickly; that would hit defensive healthcare beta first and likely compress the near-term upside in both names.

The aerospace spinout is a classic separation catalyst: passive flows, cleaner comparables, and a better multiple almost always show up first, before the market starts demanding proof on aftermarket margins and cycle durability. That means the easy money is probably in the first 1-2 months after the split, not 12 months later. The contrarian point is that investors may be underestimating how much of the rerating is mechanical rather than fundamental; once the separation bid is absorbed, the stock still has to earn its premium against peers like RTX, LHX, and TDG.

Key Decisions for Investors

• Buy MU on 3-5% pullbacks; 3-6 month upside is still attractive if memory pricing stays firm and AI capex remains elevated. Falsify the thesis if the next guidance cycle points to inventory digestion or weaker DRAM/NAND pricing.
• Long CAH / short XBI for 1-3 months as a rotation trade on defensive healthcare re-risking. Reward-to-risk is better than chasing LLY here because CAH has more room to re-rate; cover if biotech breadth improves materially after the next macro/rates move.
• Treat LLY as a hold, not a chase, and only add on sector-wide pullbacks rather than momentum strength. The stock is high-quality but crowded; the main risk is multiple compression from any access or pricing headline rather than fundamentals deteriorating.
• Use the aerospace spinout as a relative-value long versus HON or versus the industrial complex more broadly once post-separation volatility settles. The catalyst window is 1-2 months; if the stock cannot hold a higher multiple after passive buying, assume the rerating was mostly mechanical.